1. In Vivo

Medtronic “Repurposes” Spine Convention Booth To Tell Its Side of BMP Story

The firm’s bare-bones booth at the North American Spine Society annual meeting was a conspicuous sign of strains between Medtronic and the clinical group over how issues surrounding its rhBMP-2 Infuse bone graft have been presented.

A stronger financial picture in the spine space lifted the mood at this year’s North American Spine Society annual meeting in New Orleans, but the typically collegial tone was undercut a bit by a disagreement between Medtronic PLC and the group over discussions of its InFuse bone graft.

The strain was clearly evident on the exhibition floor. Rather than take its typical high profile spot, Medtronic instead “repurposed”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Pharma’s Space Trails Entering Transformative Era

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By Marion Webb

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By David Wild

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.